{
    "root": "a68e1cb3-9231-4245-8a60-7ceb92aca249",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Ciprofloxacin",
    "value": "20250522",
    "ingredients": [
        {
            "name": "CIPROFLOXACIN HYDROCHLORIDE",
            "code": "4BA73M5E37"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "CORN OIL",
            "code": "8470G57WFM"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R"
        },
        {
            "name": "SODIUM STARCH GLYCOLATE TYPE A POTATO",
            "code": "5856J3G2A2"
        },
        {
            "name": "GLYCERYL MONOCAPRYLOCAPRATE",
            "code": "G7515SW10N"
        },
        {
            "name": "POLYETHYLENE GLYCOL, UNSPECIFIED",
            "code": "3WJQ0SDW1A"
        },
        {
            "name": "POLYVINYL ALCOHOL, UNSPECIFIED",
            "code": "532B59J990"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        }
    ],
    "indications": "ciprofloxacin fluoroquinolone antibacterial indicated adults ( 18 years age older ) following infections caused designated , susceptible bacteria pediatric patients indicated : • skin skin structure infections ( 1.1 ) • bone joint infections ( 1.2 ) • complicated intra-abdominal infections ( 1.3 ) • infectious diarrhea ( 1.4 ) • typhoid fever ( enteric fever ) ( 1.5 ) • uncomplicated cervical urethral gonorrhea ( 1.6 ) • inhalational anthrax post-exposure adult pediatric patients ( 1.7 ) • plague adult pediatric patients ( 1.8 ) • chronic bacterial prostatitis ( 1.9 ) • lower respiratory tract infections ( 1.10 ) acute exacerbation chronic bronchitis • urinary tract infections ( 1.11 ) urinary tract infections ( uti ) acute uncomplicated cystitis complicated uti pyelonephritis pediatric patients • acute sinusitis ( 1.12 ) usage reduce development drug-resistant bacteria maintain effectiveness ciprofloxacin antibacterial drugs , ciprofloxacin used treat prevent infections proven strongly suspected caused bacteria . ( 1.13 )",
    "contraindications": "ciprofloxacin tablets administered orally described appropriate guidelines tables .",
    "warningsAndPrecautions": "ciprofloxacin tablets , usp available white medium capsule shape film-coated tablet containing 500 mg ciprofloxacin . 500 mg tablet engraved “ ww928 ” one side plain side . bottle 20 film-coated tablets , ndc 0904-7083-95 cartons 100 film-coated tablets ( 10 film-coated tablets per blister pack x 10 ) , ndc 0904-7083-61 - warning : unit dose package child resistant intended institutional . keep drugs reach children . store 20° 25°c ( 68° 77°f ) [ usp controlled room temperature ] . dispense tight , light-resistant container defined usp using child-resistant closure .",
    "adverseReactions": "• known hypersensitivity ciprofloxacin quinolones ( 4.1 , 5.6 , 5.7 ) • concomitant tizanidine ( 4.2 )",
    "indications_original": "Ciprofloxacin is a fluoroquinolone antibacterial indicated in adults (18 years of age and older) with the following infections caused by designated, susceptible bacteria and in pediatric patients where indicated: • Skin and Skin Structure Infections ( 1.1 ) • Bone and Joint Infections ( 1.2 ) • Complicated Intra-Abdominal Infections ( 1.3 ) • Infectious Diarrhea ( 1.4 ) • Typhoid Fever (Enteric Fever) ( 1.5 ) • Uncomplicated Cervical and Urethral Gonorrhea ( 1.6 ) • Inhalational Anthrax post-exposure in adult and pediatric patients ( 1.7 ) • Plague in adult and pediatric patients ( 1.8 ) • Chronic Bacterial Prostatitis ( 1.9 ) • Lower Respiratory Tract Infections ( 1.10 ) o Acute Exacerbation of Chronic Bronchitis • Urinary Tract Infections ( 1.11 ) o Urinary Tract Infections (UTI) o Acute Uncomplicated Cystitis o Complicated UTI and Pyelonephritis in Pediatric Patients • Acute Sinusitis ( 1.12 ) Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of ciprofloxacin and other antibacterial drugs, ciprofloxacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.13 )",
    "contraindications_original": "Ciprofloxacin tablets should be administered orally as described in the appropriate Dosage Guidelines tables.",
    "warningsAndPrecautions_original": "Ciprofloxacin Tablets, USP are available as white medium capsule shape film-coated tablet containing 500 mg ciprofloxacin. The 500 mg tablet is engraved with “WW928” from one side and plain from the other side.\n                  Bottle of 20 film-coated tablets, NDC 0904-7083-95\n                  Cartons of 100 film-coated tablets (10 film-coated tablets per blister pack x 10), NDC 0904-7083-61 - WARNING: This Unit Dose package is not child resistant and is Intended for Institutional Use Only. Keep this and all drugs out of the reach of children.\n                  Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].\n                  Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.",
    "adverseReactions_original": "• Known hypersensitivity to ciprofloxacin or other quinolones ( 4.1 , 5.6 , 5.7 ) • Concomitant administration with tizanidine ( 4.2 )"
}